Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population

被引:2
|
作者
Sutandhio, Silvia [1 ]
Furukawa, Koichi [1 ]
Kurahashi, Yukiya [1 ]
Marini, Maria Istiqomah [1 ]
Effendi, Gema Barlian [1 ]
Hasegawa, Natsumi [1 ]
Ishimaru, Hanako [1 ]
Nishimura, Mitsuhiro [1 ]
Arii, Jun [1 ]
Mori, Yasuko [1 ]
机构
[1] Kobe Univ, Ctr Infect Dis, Div Clin Virol, Grad Sch Med, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan
关键词
COVID-19; Elderly; Omicron; Vaccination; Neutralizing antibody; EXPRESSION; FUSION;
D O I
10.1016/j.jiph.2023.05.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Omicron variants with immune evasion have emerged, and they continue to mutate rapidly, raising concerns about the weakening of vaccine efficacy, and the very elderly populations are vulnerable to Coronavirus Disease 2019 (COVID-19). Therefore, to investigate the effect of multiple doses of mRNA vaccine for the newly emerged variants on these populations, cross-neutralizing antibody titers were examined against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, including BQ.1.1 and XBB. Methods: Blood samples were taken from residents at four long-term care facilities in Hyogo prefecture, Japan (median age, 91 years), after 3rd (n = 67) and 4th (n = 48) mRNA vaccinations, from April to October 2022. A live virus microneutralization assay was performed to determine the neutralizing antibody titers in participants' sera.Results: After 3rd vaccination, cross-neutralizing antibody prevalence against conventional (D614G) virus, Delta, Omicron BA.2, BA.5, BA.2.75, BQ.1.1, and XBB were 100%, 97%, 81%, 51%, 67%, 4%, and 21%, respectively. After 4th vaccination, the antibody positivity rates increased to 100%, 100%, 98%, 79%, 92%, 31%, and 52%, respectively. The 4th vaccination significantly increased cross-neutralizing antibody titers against all tested variants. Conclusion: The positivity rates for BQ.1.1 and XBB increased after 4th vaccination, although the titer value was lower than those of BA.5 and BA.2.75.Considering the rapid mutation of viruses and the efficacy of vaccines, it may be necessary to create a system that can develop vaccines suitable for each epidemic in consideration of the epidemic of the virus.(c) 2023 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1064 / 1072
页数:9
相关论文
共 50 条
  • [41] Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents
    Wang, Zheng
    Li, Dan
    Chen, Yulu
    Sun, Yeping
    Jin, Changzhong
    Hu, Caiqin
    Feng, Yi
    Su, Junwei
    Ren, Li
    Hao, Yanling
    Wang, Shuo
    Zhu, Meiling
    Liu, Ying
    Qi, Jianxun
    Zhu, Biao
    Shao, Yiming
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Comparative Analysis of Antibody Titers against the Spike Protein of SARS-CoV-2 Variants in Infected Patient Cohorts and Diverse Vaccination Regimes
    Odainic, Alexandru
    Spitzer, Jasper
    Szlapa, Jennifer Barbara
    Schade, Simon
    Kraemer, Tim Jonas
    Neuberger, Jakob
    Bode, Christian
    Steinhagen, Folkert
    Schmithausen, Ricarda Maria
    Wilbring, Gero
    Sib, Esther
    Mutters, Nico Tom
    Rabenschlag, Frederik
    Kettel, Lisa
    Woznitza, Maike
    van Bremen, Kathrin
    Peers, Tina
    Medinger, Gez
    Kudaliyanage, Anushka
    Kreutzenbeck, Maike
    Strube, Ulrike
    Johnson, Joseph M.
    Mattoon, Dawn
    Ball, Andrew J.
    Scory, Stefan
    McGuire, Richard
    Putensen, Christian
    Abdullah, Zeinab
    Latz, Catharina
    Schmidt, Susanne Viktoria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [43] Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants
    Mi, Taotao
    Wang, Tiantian
    Xu, Huifang
    Sun, Peng
    Hou, Xuchen
    Zhang, Xinwei
    Ke, Qian
    Liu, Jiawen
    Hu, Shengwei
    Wu, Jun
    Liu, Bo
    VIROLOGY, 2022, 569 : 56 - 63
  • [44] Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients
    Overheu, Oliver
    Lendowski, Simon
    Quast, Daniel R.
    Kuehn, Daniel
    Blanco, Elena Vidal
    Kraeft, Anna-Lena
    Steinmann, Eike
    Kourti, Eleni
    Lugnier, Celine
    Steinmann, Joerg
    Reinacher-Schick, Anke
    Pfaender, Stephanie
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10633 - 10644
  • [45] Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients
    Oliver Overheu
    Simon Lendowski
    Daniel R. Quast
    Daniel Kühn
    Elena Vidal Blanco
    Anna-Lena Kraeft
    Eike Steinmann
    Eleni Kourti
    Celine Lugnier
    Joerg Steinmann
    Anke Reinacher-Schick
    Stephanie Pfaender
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 10633 - 10644
  • [46] ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
    Seow, Jeffrey
    Graham, Carl
    Hallett, Sadie R.
    Lechmere, Thomas
    Maguire, Thomas J. A.
    Huettner, Isabella
    Cox, Daniel
    Khan, Hataf
    Pickering, Suzanne
    Roberts, Rebekah
    Waters, Anele
    Ward, Christopher C.
    Mant, Christine
    Pitcher, Michael J.
    Spencer, Jo
    Fox, Julie
    Malim, Michael H.
    Doores, Katie J.
    CELL REPORTS, 2022, 39 (05):
  • [47] Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination
    Bonura, Floriana
    Genovese, Dario
    Amodio, Emanuele
    Calamusa, Giuseppe
    Sanfilippo, Giuseppa Luisa
    Cacioppo, Federica
    Giammanco, Giovanni Maurizio
    De Grazia, Simona
    Ferraro, Donatella
    VACCINES, 2022, 10 (06)
  • [48] A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
    I-Jung Lee
    Cheng-Pu Sun
    Ping-Yi Wu
    Yu-Hua Lan
    I-Hsuan Wang
    Wen-Chun Liu
    Joyce Pei-Yi Yuan
    Yu-Wei Chang
    Sheng-Che Tseng
    Szu-I Tsung
    Yu-Chi Chou
    Monika Kumari
    Yin-Shiou Lin
    Hui-Feng Chen
    Tsung-Yen Chen
    Chih-Chao Lin
    Chi-Wen Chiu
    Chung-Hsuan Hsieh
    Cheng-Ying Chuang
    Chao-Min Cheng
    Hsiu-Ting Lin
    Wan-Yu Chen
    Fu-Fei Hsu
    Ming-Hsiang Hong
    Chun-Che Liao
    Chih-Shin Chang
    Jian-Jong Liang
    Hsiu-Hua Ma
    Ming-Tsai Chiang
    Hsin-Ni Liao
    Hui-Ying Ko
    Liang-Yu Chen
    Yi-An Ko
    Pei-Yu Yu
    Tzu-Jing Yang
    Po-Cheng Chiang
    Shang-Te Hsu
    Yi-Ling Lin
    Chong-Chou Lee
    Han-Chung Wu
    Mi-Hua Tao
    Journal of Biomedical Science, 29
  • [49] Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination
    Faraone, Julia N.
    Wang, Xiaolwei
    Qu, Panke
    Zheng, Yi-Min
    Vincent, Eunice
    Xu, Huanbin
    Liu, Shan-Lu
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (03)
  • [50] Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
    Padhiar, Nigam H.
    Liu, Jin-Biao
    Wang, Xu
    Wang, Xiao-Long
    Bodnar, Brittany H.
    Khan, Shazheb
    Wang, Peng
    Khan, Adil I.
    Luo, Jin-Jun
    Hu, Wen-Hui
    Ho, Wen-Zhe
    VACCINES, 2022, 10 (06)